Display options
Cite
Sonbol MB, Firwana B, Zarzour A, et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol. 2013;4(1):15-35doi: 10.1177/2040620712461047.
Sonbol, M. B., Firwana, B., Zarzour, A., Morad, M., Rana, V., & Tiu, R. V. (2013). Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Therapeutic advances in hematology, 4(1), 15-35. https://doi.org/10.1177/2040620712461047
Sonbol, Mohamad Bassam, et al. "Comprehensive review of JAK inhibitors in myeloproliferative neoplasms." Therapeutic advances in hematology vol. 4,1 (2013): 15-35. doi: https://doi.org/10.1177/2040620712461047
Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol. 2013 Feb;4(1):15-35. doi: 10.1177/2040620712461047. PMID: 23610611; PMCID: PMC3629759.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Hematol. 2013 Feb;4(1):15-35. doi: 10.1177/2040620712461047.

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

Therapeutic advances in hematology

Mohamad Bassam Sonbol, Belal Firwana, Ahmad Zarzour, Mohammad Morad, Vishal Rana, Ramon V Tiu

Affiliations

  1. Faculty of Medicine, Damascus University, Damascus, Syria.

PMID: 23610611 PMCID: PMC3629759 DOI: 10.1177/2040620712461047

Abstract

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem-cell disorders, characterized phenotypically by the abnormal accumulation of mature-appearing myeloid cells. Polycythemia vera, essential thrombocythemia, primary myelofibrosis (also known as 'BCR-ABL1-negative' MPNs), and chronic myeloid leukemia (CML) are the primary types of MPNs. After the discovery of the BCR-ABL1 fusion protein in CML, several oncogenic tyrosine kinases have been identified in 'BCR-ABL1-negative' MPNs, most importantly, JAK2V617F mutation. The similarity in the clinical characteristics of the BCR-ABL1-negative MPN patients along with the prevalence of the Janus kinase mutation in this patient population provided a strong rationale for the development of a new class of pharmacologic inhibitors that target this pathway. The first of its class, ruxolitinib, has now been approved by the food and drug administration (FDA) for the management of patients with intermediate- to high-risk myelofibrosis. Ruxolitinib provides significant and sustained improvements in spleen related and constitutional symptoms secondary to the disease. Although noncurative, ruxolitinib represents a milestone in the treatment of myelofibrosis patients. Other types of JAK2 inhibitors are being tested in various clinical trials at this point and may provide better efficacy data and safety profile than its predecessor. In this article, we comprehensively reviewed and summarized the available preclinical and clinical trials pertaining to JAK inhibitors.

Keywords: Janus kinase 2; essential thrombocythemia; polycythemia vera; primary myelofibrosis

References

  1. Lancet. 2005 Mar 19-25;365(9464):1054-61 - PubMed
  2. Invest New Drugs. 2005 Jan;23(1):31-7 - PubMed
  3. Nat Genet. 1998 Jan;18(1):84-7 - PubMed
  4. Oncogene. 2009 Jun 18;28(24):2305-13 - PubMed
  5. N Engl J Med. 2000 Apr 27;342(17):1255-65 - PubMed
  6. Leukemia. 2010 Jun;24(6):1128-38 - PubMed
  7. Blood. 2010 Feb 11;115(6):1131-6 - PubMed
  8. Leukemia. 2008 Apr;22(4):756-61 - PubMed
  9. PLoS Med. 2006 Jul;3(7):e270 - PubMed
  10. N Engl J Med. 2003 Mar 27;348(13):1201-14 - PubMed
  11. Leukemia. 2011 Mar;25(3):538-50 - PubMed
  12. Cancer Cell. 2009 Dec 8;16(6):487-97 - PubMed
  13. Nature. 2005 Apr 28;434(7037):1144-8 - PubMed
  14. Annu Rev Immunol. 1995;13:369-98 - PubMed
  15. N Engl J Med. 2012 Mar 1;366(9):787-98 - PubMed
  16. Leukemia. 2008 Jan;22(1):14-22 - PubMed
  17. Nat Rev Drug Discov. 2004 Jul;3(7):555-64 - PubMed
  18. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14845-50 - PubMed
  19. EMBO J. 1995 Apr 3;14(7):1421-9 - PubMed
  20. N Engl J Med. 2010 Sep 16;363(12):1117-27 - PubMed
  21. Blood. 2008 Jun 15;111(12):5663-71 - PubMed
  22. Blood. 2006 Sep 1;108(5):1652-60 - PubMed
  23. Blood. 2010 Aug 12;116(6):988-92 - PubMed
  24. Exp Hematol. 2006 Dec;34(12):1617-23 - PubMed
  25. Cancer Sci. 2008 Jun;99(6):1265-73 - PubMed
  26. Science. 1995 Nov 3;270(5237):800-2 - PubMed
  27. Cell. 1998 May 1;93(3):385-95 - PubMed
  28. Nature. 2009 Oct 8;461(7265):819-22 - PubMed
  29. Blood. 2004 May 15;103(10):3669-76 - PubMed
  30. Blood. 2006 Jun 1;107(11):4274-81 - PubMed
  31. J Clin Oncol. 2011 Mar 1;29(7):789-96 - PubMed
  32. Cell. 1994 Apr 22;77(2):307-16 - PubMed
  33. Blood. 2011 Mar 10;117(10):2813-6 - PubMed
  34. J Exp Med. 2004 Sep 6;200(5):569-80 - PubMed
  35. N Engl J Med. 2012 Mar 1;366(9):799-807 - PubMed
  36. Cancer Cell. 2005 Apr;7(4):387-97 - PubMed
  37. Cancer Cell. 2008 Apr;13(4):311-20 - PubMed
  38. Neoplasia. 2010 Jan;12(1):28-38 - PubMed
  39. J Med Chem. 2011 Jan 13;54(1):262-76 - PubMed
  40. Immunol Rev. 2008 Jun;223:132-42 - PubMed
  41. Blood. 2010 Jun 24;115(25):5232-40 - PubMed
  42. Blood. 2000 Aug 15;96(4):1342-7 - PubMed
  43. Proc Natl Acad Sci U S A. 2004 Oct 5;101(40):14479-84 - PubMed
  44. Blood. 2006 Nov 15;108(10):3472-6 - PubMed
  45. Nature. 1983 Nov 17-23;306(5940):277-80 - PubMed
  46. Blood. 2011 Oct 27;118(17):4595-8 - PubMed
  47. Blood. 2006 Sep 1;108(5):1551-4 - PubMed
  48. Blood. 2001 Aug 1;98(3):885-7 - PubMed
  49. Cancer Res. 2011 Nov 1;71(21):6601-10 - PubMed
  50. Blood. 2005 Jun 1;105(11):4508-15 - PubMed
  51. J Clin Oncol. 2011 Feb 1;29(4):392-7 - PubMed
  52. Br J Haematol. 2005 Sep;130(5):709-15 - PubMed
  53. Leukemia. 2010 Oct;24(10):1713-8 - PubMed
  54. J Exp Med. 2002 Jun 17;195(12):1599-611 - PubMed
  55. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10560-4 - PubMed
  56. N Engl J Med. 2010 Sep 16;363(12):1189-90 - PubMed
  57. N Engl J Med. 2007 Feb 1;356(5):459-68 - PubMed
  58. Blood. 2010 Apr 8;115(14):2919-27 - PubMed
  59. Br J Haematol. 2012 May;157(4):413-25 - PubMed
  60. Nat Rev Drug Discov. 2011 Feb;10(2):127-40 - PubMed
  61. Am J Hematol. 2012 Mar;87(3):285-93 - PubMed
  62. Mol Cancer Ther. 2010 Jul;9(7):1945-55 - PubMed
  63. Nat Rev Immunol. 2003 Nov;3(11):900-11 - PubMed
  64. J Exp Med. 2002 Jan 21;195(2):151-60 - PubMed
  65. Leuk Res. 2011 Feb;35(2):177-82 - PubMed
  66. J Invest Dermatol. 2011 Sep;131(9):1838-44 - PubMed
  67. Am J Hematol. 2011 Dec;86(12):1017-26 - PubMed
  68. Leukemia. 2007 Sep;21(9):1960-3 - PubMed
  69. Clin Cancer Res. 2009 Nov 15;15(22):6891-900 - PubMed
  70. Leukemia. 2010 Sep;24(9):1574-9 - PubMed
  71. Blood. 2008 Aug 1;112(3):844-7 - PubMed
  72. Blood. 2008 Jul 1;112(1):141-9 - PubMed
  73. Br J Haematol. 2007 May;137(3):244-7 - PubMed
  74. Leukemia. 2009 Aug;23(8):1441-5 - PubMed
  75. Leukemia. 2007 Sep;21(9):1952-9 - PubMed
  76. Semin Cell Dev Biol. 2008 Aug;19(4):385-93 - PubMed
  77. Blood. 1951 Apr;6(4):372-5 - PubMed
  78. N Engl J Med. 2005 Apr 28;352(17):1779-90 - PubMed

Publication Types